Home›Clinical trials›Ohio

GLP-1 clinical trials in Ohio: 28 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

28 GLP-1 clinical trials are recruiting at 42 sites in 17 cities across Ohio. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Ohio

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    1 site in Ohio

    NCT05390892 on ClinicalTrials.gov. See whether you qualify.

  2. Fibrosis Lessens After Metabolic Surgery

    Phase 4. The Cleveland Clinic plans to enroll 120 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

    Who can join. Adults 18 to 75, have fatty liver disease (MASLD) with liver scarring (fibrosis), BMI 35+.

    1 site in Ohio

    • Cleveland Clinic, Cleveland

    NCT06374875 on ClinicalTrials.gov. See whether you qualify.

  3. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    1 site in Ohio

    NCT06857942 on ClinicalTrials.gov. See whether you qualify.

  1. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    1 site in Ohio

    • Paramount Medical Research & Consulting, LLC, Middleburg Heights. 440-826-0742

    NCT06864026 on ClinicalTrials.gov. See whether you qualify.

  2. Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

    Phase 4. The Cleveland Clinic plans to enroll 70 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

    Who can join. Adults 18 to 70, have liver cirrhosis, BMI 35+.

    1 site in Ohio

    NCT07058155 on ClinicalTrials.gov. See whether you qualify.

  3. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    4 sites in Ohio

    • The Ohio State University Wexner Medical Center, Columbus. 833-602-2368
    • Great Lakes Gastroenterology, Mentor. 833-602-2368
    • ObjectiveHealth-DSI Research - Springboro, LLC, Springboro. 833-602-2368
    • Northshore Gastroenterology Research, Westlake. 833-602-2368

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  4. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    4 sites in Ohio

    • The Ohio State University Wexner Medical Center, Columbus. 833-602-2368
    • Great Lakes Gastroenterology, Mentor. 833-602-2368
    • ObjectiveHealth-DSI Research - Springboro, LLC, Springboro. 833-602-2368
    • Northshore Gastroenterology Research, Westlake. 833-602-2368

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

  5. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    4 sites in Ohio

    • Akron Gastro Research, Akron
    • Dayton Gastroenterology - Beavercreek, Beavercreek. 937-320-5050
    • Clinical Research Institute of Ohio - Brooklyn, Brooklyn. 440-363-4000
    • CRIOH, Westlake. 440-363-4000

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  6. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Boehringer Ingelheim plans to enroll 600 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    3 sites in Ohio

    • Diabetes & Endocrinology Associates of Stark County, Canton. 833-602-2368
    • Advanced Medical Research - Maumee, Maumee. 833-602-2368
    • New Venture Medical Research, Wadsworth. 833-602-2368

    NCT07754461 on ClinicalTrials.gov. See whether you qualify.

  7. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    2 sites in Ohio

    • Cleveland Clinic, Cleveland
    • Nationwide Children's Hospital, Columbus

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

The other 18 studies recruiting in Ohio

  1. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 460 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    2 sites in Ohio

    • Centricity Research - Ohio, Columbus
    • PriMed Clinical Research, Dayton

    NCT07253285 on ClinicalTrials.gov. See whether you qualify.

  2. Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

    Phase 3. Altimmune, Inc plans to enroll 1,800 participants.

    A study testing whether a GLP-1 and glucagon medicine from Altimmune, pemvidutide, can help people reduce liver fat.

    Who can join. Adults 18 to 75, have fatty liver disease (also called MASH or NASH), BMI 23+.

    2 sites in Ohio

    • Altimmune Clinical Study Site, Springboro
    • Altimmune Clinical Study Site, Westlake

    NCT07795164 on ClinicalTrials.gov. See whether you qualify.

  3. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Eli Lilly and Company plans to enroll 350 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Ohio

    • Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake

    NCT06937086 on ClinicalTrials.gov. See whether you qualify.

  4. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Eli Lilly and Company plans to enroll 290 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in Ohio

    • Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake

    NCT06937099 on ClinicalTrials.gov. See whether you qualify.

  5. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. VA Office of Research and Development plans to enroll 622 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    1 site in Ohio

    • Louis Stokes VA Medical Center, Cleveland, OH, Cleveland. 216-231-3241

    NCT07218354 on ClinicalTrials.gov. See whether you qualify.

  6. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in Ohio

    • Advanced Medical Research, Maumee

    NCT07564414 on ClinicalTrials.gov. See whether you qualify.

  7. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Ohio

    • Research Site, Columbus

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

  8. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Eli Lilly and Company plans to enroll 1,481 participants.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    1 site in Ohio

    NCT06143956 on ClinicalTrials.gov. See whether you qualify.

  9. TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

    Phase 2. The Cleveland Clinic plans to enroll 100 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with atrial fibrillation lose weight.

    Who can join. Adults 18 to 80, have atrial fibrillation, BMI 27+.

    1 site in Ohio

    NCT06802081 on ClinicalTrials.gov. See whether you qualify.

  10. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Eli Lilly and Company plans to enroll 240 participants.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    1 site in Ohio

    • Providence Health Partners-Center for Clinical Research, Dayton. 937-297-8994

    NCT06897475 on ClinicalTrials.gov. See whether you qualify.

  11. Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)

    Phase 2. Mansa plans to enroll 50 participants.

    A study testing whether a GLP-1 medicine, liraglutide, can help people with maturity-onset diabetes of the young (MODY) lower blood sugar.

    Who can join. Ages 10+, have maturity-onset diabetes of the young (MODY), BMI 18.5+.

    1 site in Ohio

    • Cincinnati Children's Hospital Medical Center, Cincinnati. 513-636-0002

    NCT07029009 on ClinicalTrials.gov. See whether you qualify.

  12. A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 270 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Ohio

    • Providence Center for Clinical Research, Dayton

    NCT07415954 on ClinicalTrials.gov. See whether you qualify.

  13. Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants

    Phase 2. Biomea Fusion Inc plans to enroll 60 participants.

    A study testing whether an investigational medicine from Biomea Fusion, icovamenib, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 70, have type 2 diabetes, BMI 25+.

    1 site in Ohio

    • Diabetes and Endocrinology Associates of Stark County, Canton

    NCT07502508 on ClinicalTrials.gov. See whether you qualify.

  14. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Novo Nordisk A/S plans to enroll 230 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in Ohio

    • Family Practice Center of Wadsworth Inc., Wadsworth

    NCT07639021 on ClinicalTrials.gov. See whether you qualify.

  15. Preoperative Weight Loss for Open Abdominal Wall Reconstruction

    Benjamin T. Miller plans to enroll 258 participants.

    A study of a GLP-1 medicine, semaglutide, in people with abdominal wall hernia.

    Who can join. Adults 18+, have abdominal wall hernia, BMI 40+.

    1 site in Ohio

    • Cleveland Clinic Main Campus, Cleveland. 2164068573

    NCT05925959 on ClinicalTrials.gov. See whether you qualify.

  16. Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy

    Ian J. Neeland, MD plans to enroll 108 participants.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18 to 80, have obesity or are overweight, BMI 27+.

    1 site in Ohio

    • University Hospitals Cleveland Medical Center, Clevland. 216-844-5965

    NCT07244445 on ClinicalTrials.gov. See whether you qualify.

  17. Dietary Peanuts and Nutrition-Related Outcomes

    Ian J. Neeland, MD plans to enroll 64 participants.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18 to 80, have obesity or are overweight, BMI 27+.

    1 site in Ohio

    • University Hospitals Cleveland Medical Center, Clevland. 216-844-5965

    NCT07244458 on ClinicalTrials.gov. See whether you qualify.

  18. Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

    Ohio State University plans to enroll 300 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with diabetes lose weight.

    Who can join. Adults 18+, have obesity or are overweight.

    1 site in Ohio

    NCT07702461 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.